Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $9.80 and last traded at $10.37, with a volume of 242440 shares. The stock had previously closed at $12.10.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush reissued an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday. Finally, HC Wainwright started coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $22.33.
Check Out Our Latest Research Report on TLX
Telix Pharmaceuticals Stock Down 13.8%
The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The company has a 50-day moving average of $14.20 and a 200 day moving average of $16.16.
Hedge Funds Weigh In On Telix Pharmaceuticals
Several institutional investors have recently bought and sold shares of TLX. Private Advisor Group LLC bought a new position in Telix Pharmaceuticals in the 1st quarter valued at $170,000. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals during the first quarter worth $451,000. Blair William & Co. IL bought a new stake in shares of Telix Pharmaceuticals during the second quarter worth $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at about $297,000. Finally, Pier Capital LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at about $3,037,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
